Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap

May 16 2017

• By Malcolm Spicer

GoldKeyInPuzzle_1200x675

Related Content

The Future Of OTCs: Self-Selection Meets Diagnostics, Genetic Personalization

May 16 2011

Light Still On For Switches After Pfizer Pulls Plug On OTC <em>Lipitor</em>

Aug 03 2015

FDA To Tackle Critical Generics Issue In Switch Paradigm Debate

Mar 12 2012

Bring Naloxone To Opioid Overdoses: FDA Crowd-Sources Smartphone Apps

Sep 23 2016

CDER Talks Switches, Monograph 'More Than Ever,' But Mum On Changes

May 23 2016

Room For Innovative Switches Could Lurk In Existing FDA Framework

Oct 29 2014

Related Companies

Pfizer Inc.

Sanofi

Eli Lilly and Company

Adapt Pharma Limited

Additional Topics

United States Prescription To OTC Switch Drug Approval Standards Regulation OTC Drugs Consumer

More from Rx-to-OTC Switch

More from Health

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.